MAP2K7 and melanoma: To the best of our knowledge, this is the initial trial testing the neoadjuvant combination of BRAF and MEK inhibition with anti-PD-L1 immunotherapy in high risk surgically resectable Stage III BRAFm melanoma as well as testing neoadjuvant anti-PD-L1 immunotherapy with MEK inhibition for patients with BRAFwt disease.